Top-News
Mittwoch,
04.08.2021 06:00
von
PR Newswire
| Aufrufe: 164
United Therapeutics Corporation Reports Second Quarter 2021 Financial Results
Wirtschaftsnachrichten (Symbolbild).
pixabay.com
PR Newswire
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Aug. 4, 2021
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Aug. 4, 2021 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced its financial results for the quarter ended June 30, 2021. Total revenue in the second quarter of 2021 grew 23% year over year to $446.5 million, compared to $362.0 million in the second quarter of 2020.
"We are pleased to continue our expansion into new indications outside of WHO Group 1 PAH with strong Tyvaso financial results, and with patient enrollment continuing in our PERFECT and TETON phase 3 studies in COPD-associated pulmonary hypertension and in IPF, respectively," said Martine Rothblatt, Ph.D., Chairperson and Chief Executive Officer of United Therapeutics. "Meanwhile, we are also focused on expanding our medical armamentarium for PAH with the continued progress of our phase 3 studies of once-daily ralinepag, and with our next-generation treprostinil molecules and delivery systems."
"As we build traction with the Tyvaso PH-ILD launch, I am also tremendously excited about the uptake of all of our products during the past quarter," said Michael Benkowitz, President and Chief Operating Officer of United Therapeutics. "Indeed, we are currently seeing some of the highest levels of referrals of Tyvaso and Orenitram since their launches and we're well on our way to our goal of doubling the number of Tyvaso patients on therapy by the end of 2022."
SECOND QUARTER 2021 FINANCIAL RESULTS
Key financial highlights include (dollars in millions, except per share data):
| | Three Months Ended June 30, | | Dollar | | Percentage | |||||||||
| | 2021 | | 2020 | | | |||||||||
| | | | | | | | | |||||||
| Revenues | $ | 446.5 | | | $ | 362.0 | | | $ | 84.5 | | | 23 | % |
| Net income | $ | 172.6 | | | $ | 107.1 | | | $ | 65.5 | | | 61 | % |
| Non-GAAP earnings(1) | $ | 193.5 | | | $ | 163.2 | | | $ | 30.3 | | | 19 | % |
| Net income, per basic share | $ | 3.85 | | | $ | 2.43 | | | $ | 1.42 | | | 58 | % |
| Net income, per diluted share | $ | 3.65 | | | $ | 2.41 | | | $ | 1.24 | | | 51 | % |
| Non-GAAP earnings, per diluted share(1) | $ | 4.09 | | | $ | 3.68 | | | $ | 0.41 | | | 11 | % |
| | |
| (1) | See definition of non-GAAP earnings, a non-GAAP financial measure, and a reconciliation of net income to non-GAAP earnings below. |
Revenues
The table below summarizes the components of total revenues (dollars in millions):
| | Three Months Ended June 30, | | Dollar | | Percentage Change | |||||||||
| | 2021 | | 2020 | | | |||||||||
| Net product sales: | | | | | | | | |||||||
| Remodulin® | $ | 139.8 | | | $ | 119.0 | | | $ | 20.8 | | | 17 | % |
| Tyvaso® | 153.8 | | | 119.2 | | | 34.6 | | | 29 | % | |||
| Orenitram® | 76.2 | | | 75.4 | | | 0.8 | | | 1 Werbung Mehr Nachrichten zur United Therapeutics Aktie kostenlos abonnieren
E-Mail-Adresse
Bitte überprüfe deine die E-Mail-Adresse.
Benachrichtigungen von ARIVA.DE (Mit der Bestellung akzeptierst du die Datenschutzhinweise) -1  Vielen Dank, dass du dich für unseren Newsletter angemeldet hast. Du erhältst in Kürze eine E-Mail mit einem Aktivierungslink. Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte. Andere Nutzer interessierten sich auch für folgende News | ||||
